Esperion Therapeutics (ESPR) Other financing activities (2012 - 2026)

Esperion Therapeutics' Other financing activities history runs 14 years deep, the most recent figure standing at $16.2 million for Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (up 193.8% YoY) and the FY2025 annual result came in at $10.3 million, down 30.12% from the prior year.
• Other financing activities was $16.2 million for Q1 2026 at Esperion Therapeutics, up from $10.3 million in the prior quarter.
• Across five years, Other financing activities topped out at $16.2 million in Q1 2026 and bottomed at -$14.8 million in Q3 2024.
• A 4-year average of $5.9 million and a median of $9.0 million in 2024 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2024 — Other financing activities surged 70276.19% — and 2025, when it slipped 29.98%.
• Esperion Therapeutics' Other financing activities stood at $21000.0 in 2023, then jumped by 70276.19% to $14.8 million in 2024, then fell by 29.98% to $10.3 million in 2025, then surged by 56.72% to $16.2 million in 2026.
• Business Quant data shows ESPR's Other financing activities at $16.2 million in Q1 2026, $10.3 million in Q4 2025, and $14.8 million in Q4 2024.